Clinical Trial Update: Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating euthyroid hypothyroxinemia in metastatic breast cancer was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Aultman Health Foundation | Conditions: Metastatic Breast Cancer, Thyroid Dysfunction | Phase 2 | Status: TERMINATED | Results posted: 2022-05-13